M&A Deal Summary |
|
---|---|
Date | 2024-03-04 |
Target | Cimerli |
Sector | Life Science |
Buyer(s) | Sandoz International |
Sellers(s) | Coherus Biosciences |
Deal Type | Divestiture |
Deal Value | 170M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Sandoz International GmbH is a developer, manufacturer and markets generic pharmaceutical products focused on biosimilars, injectables, inhalers and transdermal patches.
DEAL STATS | # |
---|---|
Overall | 5 of 5 |
Sector (Life Science) | 4 of 4 |
Type (Divestiture) | 4 of 4 |
State (California) | 1 of 1 |
Country (United States) | 2 of 2 |
Year (2024) | 1 of 1 |
Size (of disclosed) | 4 of 4 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-02-11 |
GSK - Cephalosporin Antibiotics Business
Brentford, United Kingdom GSK's Cephalosporin Antibiotics Business is a provider of antibiotics used to treat a range of bacterial infections. |
Buy | $500M |
Category | Company |
---|---|
Founded | 2010 |
Sector | Life Science |
Employees | 249 |
Revenue | 257M USD (2023) |
Coherus Biosciences is a biotechnology company focused on developing products. Coherus BioSciences was founded in 2010 and is based in Redwood City, California.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Divestiture) | 1 of 1 |
State (California) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2024) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2023-06-16 |
Surface Oncology
Cambridge, Massachusetts, United States Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned programs: SRF388, a Phase 2 program targeting IL-27, and SRF114, a Phase 1 program that selectively depletes regulatory T cells in the tumor microenvironment via targeting CCR8. Surface Oncology was founded in 2014 and is based in Cambridge, Massachusetts. |
Buy | $65M |